Last Price$302.80.6%
Market Cap$17.3B
LTM Cash & Cash Equivalents
$4,662.0M
YoY Growth
-3.8%
3Y CAGR
+1.7%
5Y CAGR
+13.7%
Stock quality & Intrinsic value
6/10
37.0% undervalued
Molina Healthcare, Inc. Cash & Cash Equivalents
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $249.2M | $403.7M | $459.1M | $387.2M | $469.5M | $455.9M | $493.8M | $795.8M | $935.9M | $1,539.1M | $2,329.0M | $2,819.0M | $3,186.0M | $2,826.0M | $2,452.0M | $4,154.0M | $4,438.0M | $4,006.0M | $4,848.0M | $4,662.0M |
Overvalued or undervalued?
Check the intrinsic value for MOH
and see if it's the right time to invest.
Molina Healthcare, Inc. (MOH) Cash & Cash Equivalents comparison analysis
General
LTM Cash & Cash Equivalents
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Molina Healthcare, Inc.MOH
$4,662.0M
(3.8%)
1.7%
13.7%
Median Peer Set
$4,885.5M
0.6%
(0.1%)
5.8%
UnitedHealth Group IncorporatedUNH
$29.1B
14.5%
10.8%
21.5%
Centene CorporationCNC
$14.1B
(18.2%)
2.3%
3.0%
CVS Health CorporationCVS
$8,586.0M
4.8%
(3.0%)
8.6%
Elevance Health Inc.ELV
$8,288.0M
27.0%
19.3%
10.9%
Cigna CorporationCI
$7,550.0M
(3.5%)
14.1%
10.3%
Humana Inc.HUM
$2,221.0M
(52.7%)
(13.2%)
(11.3%)
Oscar Health, Inc.OSCR
$1,527.2M
(18.3%)
11.4%
N/A
Alignment Healthcare, Inc.ALHC
$432.9M
113.3%
(2.5%)
N/A
Clover Health Investments, Corp.CLOV
$194.5M
58.3%
(13.4%)
23.5%
Bright Health Group, Inc.BHG
$87.3M
(81.3%)
(43.7%)
N/A
MOH key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,650.1 40.4% | 2,005.0 21.5% | 2,492.5 24.3% | 3,112.4 24.9% | 3,669.4 17.9% | 4,086.0 11.4% | 4,769.9 16.7% | 6,028.8 26.4% | 6,588.9 9.3% | 9,666.6 46.7% | 14,072.0 45.6% | 17,711.0 25.9% | 19,883.0 12.3% | 18,890.0 (5.0%) | 16,829.0 (10.9%) | 19,423.0 15.4% | 27,771.0 43.0% | 31,974.0 15.1% | 34,072.0 6.6% | 40,650.0 19.3% |
| Cost of Goods Sold (COGS) | 1,424.9 | 1,678.7 | 2,080.1 | 2,621.3 | 3,176.2 | 3,449.5 | 4,004.0 | 5,397.0 | 5,713.6 | 8,616.1 | 12,434.0 | 15,941.0 | 18,003.0 | 16,266.0 | 14,394.0 | 16,746.0 | 24,491.0 | 28,048.0 | 29,738.0 | 0.0 |
% margin | 225.2 13.6% | 326.3 16.3% | 412.4 16.5% | 491.1 15.8% | 493.1 13.4% | 636.5 15.6% | 766.0 16.1% | 631.8 10.5% | 875.3 13.3% | 1,050.5 10.9% | 1,638.0 11.6% | 1,770.0 10.0% | 1,880.0 9.5% | 2,624.0 13.9% | 2,435.0 14.5% | 2,677.0 13.8% | 3,280.0 11.8% | 3,926.0 12.3% | 4,334.0 12.7% | 40,650.0 100.0% |
| Operating Expenses | 179.4 | 250.5 | 314.0 | 378.4 | 437.3 | 531.5 | 621.2 | 596.3 | 738.7 | 857.6 | 1,251.0 | 1,532.0 | 1,731.0 | 1,432.0 | 1,385.0 | 1,599.0 | 2,260.0 | 2,545.0 | 2,761.0 | 38,943.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 163.3 | 229.1 | 285.3 | 344.8 | 399.1 | 346.0 | 415.9 | 532.6 | 666.0 | 764.7 | 1,147.0 | 1,393.0 | 1,594.0 | 1,333.0 | 1,296.0 | 1,480.0 | 2,068.0 | 2,311.0 | 2,462.0 | 2,743.0 |
% margin | 45.8 2.8% | 75.8 3.8% | 98.3 3.9% | 112.6 3.6% | 57.4 1.6% | 105.0 2.6% | 80.2 1.7% | 35.5 0.6% | 136.6 2.1% | 192.9 2.0% | 387.0 2.8% | 238.0 1.3% | (555.0) (2.8%) | 1,131.0 6.0% | 1,044.0 6.2% | 1,078.0 5.6% | 1,020.0 3.7% | 1,173.0 3.7% | 1,573.0 4.6% | 1,707.0 4.2% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 87.0 | 102.0 | 120.0 | 110.0 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 4.6 | 8.7 | 13.8 | 15.5 | 15.5 | 16.8 | 52.1 | 56.8 | 67.0 | 101.0 | 118.0 | 115.0 | 87.0 | 102.0 | 120.0 | 110.0 | 109.0 | 118.0 |
| Pre-tax Income | 43.9 | 73.5 | 93.7 | 103.9 | 43.6 | 89.5 | 64.7 | 19.1 | 81.1 | 135.3 | 322.0 | 137.0 | (612.0) | 999.0 | 972.0 | 961.0 | 875.0 | 1,063.0 | 1,464.0 | 1,589.0 |
% effective tax rate | 16.3 37.1% | 27.7 37.8% | 35.4 37.7% | 41.5 39.9% | 12.7 29.2% | 34.5 38.6% | 43.8 67.8% | 9.3 48.6% | 36.3 44.8% | 72.7 53.8% | 179.0 55.6% | 129.0 94.2% | (100.0) 16.3% | 292.0 29.2% | 235.0 24.2% | 288.0 30.0% | 216.0 24.7% | 271.0 25.5% | 373.0 25.5% | 410.0 25.8% |
% margin | 27.6 1.7% | 45.7 2.3% | 58.3 2.3% | 62.4 2.0% | 30.9 0.8% | 55.0 1.3% | 20.8 0.4% | 9.8 0.2% | 52.9 0.8% | 62.2 0.6% | 143.0 1.0% | 8.0 0.0% | (512.0) (2.6%) | 707.0 3.7% | 737.0 4.4% | 673.0 3.5% | 659.0 2.4% | 792.0 2.5% | 1,091.0 3.2% | 1,179.0 2.9% |
| EPS | 0.67 | 1.09 | 1.37 | 1.50 | 0.79 | 1.34 | 0.45 | 0.21 | 1.16 | 1.33 | 2.75 | 0.93 | (9.14) | 10.61 | 11.85 | 11.41 | 11.40 | 13.70 | 18.71 | 20.43 |
| Diluted EPS | 0.65 | 1.08 | 1.37 | 1.50 | 0.79 | 1.32 | 0.45 | 0.21 | 1.13 | 1.29 | 2.58 | 0.92 | (9.14) | 10.55 | 11.48 | 11.24 | 11.25 | 13.54 | 18.78 | 20.43 |
% margin | 60.9 3.7% | 97.3 4.9% | 126.3 5.1% | 146.3 4.7% | 94.0 2.6% | 165.8 4.1% | 210.2 4.4% | 118.3 2.0% | 214.1 3.2% | 332.7 3.4% | 514.0 3.7% | 488.0 2.8% | (316.0) (1.6%) | 1,241.0 6.6% | 1,148.0 6.8% | 1,151.0 5.9% | 1,126.0 4.1% | 1,349.0 4.2% | 1,744.0 5.1% | 1,893.0 4.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Molina Healthcare, Inc.'s Cash & Cash Equivalents?
As of today, Molina Healthcare, Inc.'s last 12-month Cash & Cash Equivalents is $4,662.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Molina Healthcare, Inc.'s Cash & Cash Equivalents growth rate?
Over the last year, Molina Healthcare, Inc.'s Cash & Cash Equivalents growth was (3.8%). The average annual Cash & Cash Equivalents growth rates for Molina Healthcare, Inc. have been 0.4% over the past three years, 13.7% over the past five years.
3) Is Molina Healthcare, Inc.'s Cash & Cash Equivalents growth rate Good?
Over the last year, Molina Healthcare, Inc.'s Cash & Cash Equivalents growth was (3.8%), which is lower than industry growth of (0.3%). It indicates that Molina Healthcare, Inc.'s Cash & Cash Equivalents growth is Bad.